<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC3358196/results/search/test_trace/results.xml">
  <result pre="NW9 5EQ, UK; email: richard.pebody@hpa.org.uk ppub: 2011-6176990999 TOC Summary: Early" exact="treatment" post="of primary case-patients and prophylaxis of household contacts provides"/>
  <result pre="years of age (18.9% vs. 1.2%, p&amp;lt;0.001). Early (&amp;lt;48 hours)" exact="treatment" post="of primary case-patients reduced SAR (4.5% vs. 10.6%, p"/>
  <result pre="SAR in child contacts was 33.3% (10/30) when the primary" exact="contact" post="was a woman and 2.9% (1/34) when the primary"/>
  <result pre="contact was a woman and 2.9% (1/34) when the primary" exact="contact" post="was a man (p = 0.010). Of 53 confirmed"/>
  <result pre="received AV prophylaxis. The effectiveness of AV prophylaxis in preventing" exact="infection" post="was 92%. Keywords: viruses influenza pandemic prophylaxis pandemic (H1N1)"/>
  <result pre="strategy until July 2009 that involved rapid case ascertainment, early" exact="treatment" post="with antiviral drugs (AVs), and postexposure prophylaxis of patients’"/>
  <result pre="case definitions were used: 1) virologically confirmed cases were persons" exact="testing" post="positive for pandemic (H1N1) 2009 virus by specific reverse"/>
  <result pre="of the confirmed household primary case; and 3) acute respiratory" exact="infection" post="(ARI) cases were persons experiencing &amp;gt;1 respiratory symptom (as"/>
  <result pre="of onset of the confirmed household primary case. A household" exact="contact" post="was any person who lived in the same household"/>
  <result pre="AVs were administered &amp;lt;24 hours before illness onset. Any asymptomatic" exact="contact" post="who received AVs was classified as having prophylaxis. For"/>
  <result pre="household contacts. At initial interview, contacts were asked about their" exact="contact" post="history with the primary case-patient; clinical history, including recent"/>
  <result pre="did not have case-defining illness. To ensure that all contacts" exact="testing" post="positive for pandemic (H1N1) 2009 virus were identified, the"/>
  <result pre="years), gender, AV prophylaxis (yes or no), and timing of" exact="treatment" post="for the primary case-patient (&amp;lt;48 hours vs. &amp;gt;48 hours)"/>
  <result pre="on household SAR while accounting for timing of administration. A" exact="contact" post="enters the model with time zero at index onset,"/>
  <result pre="time is defined up until onset of disease in the" exact="contact" post="(failure), or excluded at the end of the 2-week"/>
  <result pre="by using Cox regression, adjusted for age, sex, and AV" exact="treatment" post="of the primary case-patient &amp;lt;48 hours. This approach accounted"/>
  <result pre="real-time RT-PCR for pandemic (H1N1) 2009 virus. Pandemic (H1N1) 2009" exact="diagnosis" post="was confirmed before June 2009 by sequencing the influenza"/>
  <result pre="Primary and co-primary confirmed case-patients with pandemic (H1N1) 2009 virus" exact="infection" post="and household contacts, by sex, age, and prophylaxis status,"/>
  <result pre="indicated. Of the primary case-patients, 245 (95.7%) had received AV" exact="treatment" post="(of whom 116/118 with information had received oseltamivir). Among"/>
  <result pre="had received oseltamivir). Among treated case-patients, 104 (42.4%) had started" exact="treatment" post="&amp;lt;48 hours of disease onset, with median time to"/>
  <result pre="&amp;lt;48 hours of disease onset, with median time to AV" exact="treatment" post="of 3 days (IQR 1–5). Household Close Contacts The"/>
  <result pre="AV of 9 days (IQR 8–10). Only 8 contacts received" exact="treatment" post="for &amp;lt;5 days. Table 3 Confirmed SAR of pandemic"/>
  <result pre="date of household primary case-patient with pandemic (H1N1) 2009 virus" exact="infection" post="until antiviral prophylaxis started, N = 352, United Kingdom,"/>
  <result pre="4 Univariate and multivariate analysis of pandemic (H1N1) 2009 virus" exact="infection" post="SAR for virologically confirmed cases of pandemic (H1N1) 2009"/>
  <result pre="444 8 1.8 (0.8–3.9) &amp;lt;0.001 0.05 (0.02–0.09) &amp;lt;0.001 Primary case-patient" exact="treatment" post="&amp;gt;48 h 453 48 10.6 (8.1–13.8) 1.0, baseline &amp;lt;48"/>
  <result pre="was significantly lower in contacts whose primary case-patient had received" exact="treatment" post="&amp;lt;48 hours of onset rather than after 48 hours"/>
  <result pre="2.0–138.8; p = 0.010). Table 5 Pandemic (H1N1) 2009 virus" exact="infection" post="SAR, by age of patient with virologically confirmed primary"/>
  <result pre="received AV prophylaxis had a significantly reduced risk of confirmed" exact="infection" post="than those not treated (Table 4). Finally, the adjusted"/>
  <result pre="case-patient were significantly lower when the primary case-patient had received" exact="treatment" post="&amp;lt;48 hours of onset. SAR for Clinically Confirmed Cases"/>
  <result pre="6 Univariate and multivariate analysis of pandemic (H1N1) 2009 virus" exact="infection" post="SAR for clinically confirmed cases of influenza-like illness, by"/>
  <result pre="444 18 4.1 (2.3–7.1) &amp;lt;0.001 0.05 (0.02–0.09) &amp;lt;0.001 Primary case-patient" exact="treatment" post="&amp;gt;48 h 445 55 12.4 (9.6–15.8) 1.0, baseline &amp;lt;48"/>
  <result pre="The effect of age, AV prophylaxis of contacts, and early" exact="treatment" post="of case-patients were generally similar for both ILI and"/>
  <result pre="7 Univariate and multivariate analysis of pandemic (H1N1) 2009 SAR" exact="infection" post="for acute respiratory infection, by gender, age group and"/>
  <result pre="443 34 7.7 (4.5–12.7) &amp;lt;0.001 0.02 (0.01–0.03) &amp;lt;0.001 Primary case-patient" exact="treatment" post="&amp;gt;48 h 435 79 18.2 (14.8–22.1) 1, baseline &amp;lt;48"/>
  <result pre="(95% CI 0.02–0.27). Results were similar after adjusting for AV" exact="treatment" post="of the primary case-patient, age, and sex (HR 0.09,"/>
  <result pre="8 Multivariable survival analysis of for pandemic (H1N1) 2009 virus" exact="infection" post="SAR with virologic, influenza-like-illness, and acute respiratory infection endpoints,"/>
  <result pre="2009 virus infection SAR with virologic, influenza-like-illness, and acute respiratory" exact="infection" post="endpoints, by gender, age group, and prophylaxis, United Kingdom,"/>
  <result pre="Hazard ratio (95% confidence interval) Virologic Influenza-like illness Acute respiratory" exact="infection" post="Sex M 1 (reference) 1 (reference) 1 (reference) F"/>
  <result pre="Treated 0.09 (0.03–0.32) 0.27 (0.13–0.57) 0.27 (0.15– 0.48) Index case-patient" exact="treatment" post="&amp;gt;48 h 1 (reference) 1 (reference) 1 (reference) &amp;lt;48"/>
  <result pre="Serologic studies will provide important insights into the rates of" exact="infection" post="(both symptomatic and asymptomatic in a household setting). Recent"/>
  <result pre="household study, found that postexposure prophylaxis reduced the incidence of" exact="infection" post="in close household contacts by 89% (25). Our study"/>
  <result pre="translate into reduced likelihood of secondary transmission and supports rapid" exact="treatment" post="of patients to reduce household transmission. The observation that"/>
  <result pre="or adult to adult, is also consistent with the increasing" exact="prevalence" post="of cross-reacting antibodies against pandemic (H1N1) 2009 virus with"/>
  <result pre="and shorter duration of excretion, women transmitted pandemic (H1N1) 2009" exact="infection" post="as efficiently as child primary case-patients. This suggests adult"/>
  <result pre="account for this. Second, case finding was based on a" exact="screening" post="algorithm requiring fever. Thus, primary cases of pandemic influenza"/>
  <result pre="contact, whereas if the primary case-patient was identified later, close" exact="contact" post="may not have been avoided. However, a time-varying survival"/>
  <result pre="confounding factor. Finally, we assumed household secondary case-patients acquired their" exact="infection" post="after contact with a defined primary case-patient in the"/>
  <result pre="Finally, we assumed household secondary case-patients acquired their infection after" exact="contact" post="with a defined primary case-patient in the household, rather"/>
  <result pre="were generally higher than those of seasonal influenza. Timely AV" exact="treatment" post="of primary case-patients and prophylaxis was effective in protecting"/>
  <result pre="of AV did allow spread. Prompt AV administration (either as" exact="treatment" post="or prophylaxis) reduces symptomatic SARs. Suggested citation for this"/>
  <result pre="collab: Centers for Disease Control and PreventionSwine influenza A (H1N1)" exact="infection" post="in two children–Southern California, March–April 2009.MMWR Morb Mortal Wkly"/>
  <result pre="GrayJ, et al. Evaluation of four real-time PCR assays for" exact="detection" post="of influenza A(H1N1)v viruses. Euro Surveill. 2009;14:pii:19230. 19. ViboudC,"/>
  <result pre="NgS, CowlingBJ, FangVJ, ChanKH, IpDK, ChengCK, et al.Effects of oseltamivir" exact="treatment" post="on duration of clinical illness and viral shedding and"/>
  <result pre="HeiderA, et al.Shedding and transmission of novel influenza virus A/H1N1" exact="infection" post="in households—Germany, 2009.Am J Epidemiol. 2010;171:1157–6410.1093/aje/kwq07120439308 25. WelliverR, MontoAS,"/>
  <result pre="HardelidP, StanfordE, AndrewsN, ZambonMCIncidence of 2009 pandemic influenza A H1N1" exact="infection" post="in England: a cross-sectional serological study.Lancet. 2010;375:1100–810.1016/S0140-6736(09)62126-720096450 31. McClellanK,"/>
  <result pre="influenza virus.N Engl J Med. 2009;361:1945–5210.1056/NEJMoa090645319745214 33. HallCB, DouglasRGJrNosocomial influenza" exact="infection" post="as a cause of intercurrent fevers in infants.Pediatrics. 1975;55:673–71168894"/>
 </snippets>
</snippetsTree>
